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The in vitro results suggest that gold kiwifruit has 
the potential to influence immune responses, 
up-regulating key cells and cytokines for effective 
protective immunity. The possibility that gold kiwifruit 
can modulate the immune system in a positive way means 
that it may improve health and wellbeing by leading to 
lower incidences of common infections such as colds and 
flu or a reduction in the severity or length of symptoms. 
The results of intervention trials in two groups at higher 
risk of contracting colds and flu, older adults and young 
children, provide evidence that consumption of gold 
kiwifruit in these groups can reduce the symptoms of 
colds and flu and the overall incidence of infection. 
Whether these effects on infection are due to better 
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Rhizoma Drynaria (RD) has been widely used for healing bone fractures or related diseases in traditional Chinese medicine. 
The present study was designed to determine if RD total flavonoids (RDTF) could exert estrogen-like protective actions on bone. 
Young C57/BL6J mice were ovariectomized (OVX) and treated orally with RDTF (0.087, 0.173 or 0.346 mg/g/day), 17β-estradiol 
(2μg/g/day) or its vehicle for 6 weeks. Bone mineral densities (BMD) was measured by peripheral quantitative computed 
tomography (pQCT). Rat osteoblast-like UMR-106 cells were co-incubated with ER antagonist ICI 182, 780 to determine if the 
effects of RDTF on osteoblastic functions were ER-dependent. The functional transactivation of ER-α and ER-β as well as 
ER-αphosphorylation by RDTF were also studied. RDTF increased trabecular-rich BMD at distal femur and lumbar spine in OVX 
mice. 0.173 mg/g/day was most effective in improving bone properties in OVX mice. The stimulatory effects of RDTF on 
osteoblastic functions could be abolished by co-incubation with ICI 182, 780 in UMR-106 cells. Transient transfection study 
indicated that RDTF dose-dependently stimulated ERE-dependent luciferase activity in UMR-106 cells via ER-α and ER-β. 




Osteoporosis is a condition characterized by low bone 
mineral density and microarchitectural deterioration of 
bone tissue, resulting in an increase risk in fracture(1). 
Increased risks of morbidity and mortality were found in 
osteoporotic patients suffering from hip and vertebral 
fractures(2). Estrogen replacement therapy (ERT), a major 
regimen for the management of osteoporosis, was recently 
found to be associated with an increased risk in developing 
stroke and breast cancer in postmenopausal women(3). 
Thus, affordable alternative approaches with minimal side 
effects, such as the use of traditional Chinese medicine 
(TCM), for the management of postmenopausal 
osteoporosis are worth exploring. This is particularly 
important for aging population in the developing countries 
as majority of the patients could not afford long term use 
of high cost medications. 
One of the most frequently used herb in Chinese 
medicine for treatment of bone fractures is Rhizoma 
Drynaria. It is characterized as the dried rhizome of 
perennial pteridophyte Drynaria Fortunei (Kunze) J. Smith 
(Polypodiaceae). Its Chinese name is ‘Gu Sui Bu’, which 
means bone fractures healer. It is recognized as a 
‘kidney-tonifying’ herb in the TCM formulae for treatment 
of bone related disorders such as osteoporosis and bone 
fractures for many years in China. The bone protective 
effects of RD have been reported previously(4). Its crude 
extract has been shown to promote osteoblast 
differentiation and mineralization in pre-osteoblastic 
MC3T3-E1 cells through regulation of bone 
morphogenetic protein-2(4). Wong et al. reported that RD 
crude extract exerted strong effects on bone formation in 
mice(5). Jia et al reported that RD mimicked estrogen in 
maintaining normal trabecular structure and suppressing 
bone turnover rate of postmenopausal osteoporosis. Total 
flavonoid fraction of RD was previously demonstrated to 
exert strong anti-oxidative effect as well as osteoprotective 
effect(6). RDTF was found to significantly restore 
OVX-induced bone loss in rats. In addition, it was found 
not only to suppress osteoclastic cell activity but also to 
promote osteoblastic cell proliferation in vitro(6). However, 
the optimal dosage of RDTF for exerting bone protective 
effects in vivo has not been characterized. 
The present study aimed to systematically 
characterize the dose-dependent effects of RDTF on bone 
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properties in OVX mice, followed by the study of its 
effects on rat osteoblast-like UMR 106 cells. It is hope that 
the studies would provide evidence to support the use of 
Rhizoma Drynaria as alternatives for prevention and 
treatment of postmenopausal osteoporosis. 
 
MATERIALS AND METHODS 
 
I. Preparation of Rhizoma Drynaria Total Flavonoid 
Extract 
 
Rhizomes of Drynaria fortune were collected in 
Guizhow province, China in 2005 and were identified by 
Professor Zhou Rong-Han (Chinese Pharmaceutical 
University, Nanjing, Jiansu, China). The total flavanoid 
fraction of rhizomes of D. fortune (50 kg) were preapared 
by extraction with 60% ethanol and chromatographed on a 
D-101 macroporous resin column (Φ25 × 150 cm) with 
gradients of water and 30, 50 and 95% alcohol. High 
performance of liquid chromatography (HPLC) was 
performed on a Shimadzu C18 column (Φ250 × 4.6 cm) in 
Agilent series 1100 (USA) to analyze the compounds in 
the total flavonoid extract of Rhizoma Drynaria. 
 
II. Animal Study 
 
Sixty one-month old female C57/BL6J mice from the 
Chinese University of Hong Kong were housed in 
environmentally controlled central animal facilities. The 
mice were either sham-operated or ovariectomized (OVX) 
at the age of one month. After recovering for two weeks, 
the mice were randomly selected and divided into 6 groups. 
One group was sham vehicle (2% Ethanol), the others 
were OVX vehicle; OVX 17β-estradiol (2µg/g/day) and 3 
groups of OVX RD total flavonoid (RDTF) extract: Low 
dose: 0.087; Medium dose: 0.173; and High dose: 0.347 
mg/g/day. Treatments were administrated orally to the 6 
groups of animals for 6 weeks. Animals were pair-fed with 
diet containing 0.6% Ca and 0.65% P (TD 98005, Teklad, 
Madison, WI) and were allowed free access to water 
throughout the course of the studies as previously 
described(7). The care and treatment protocol was approved 
by the Animal Ethics Committee of the Hong Kong 
Polytechnic University. Urine samples were collected one 
day before sacrifice. Blood samples, uteri and bone 
specimens (femur, tibia and lumbar spine) were collected 
at the end of the experiment.  
 
III. Assessment ofBone Propertiesby Peripheral Quan- 
titative Computed Tomography (pQCT) 
 
Trabecular and cortical bone densities of left femur, 
tibia and lumbar spine region L1 were measured using 
StraTec XCT2000 machine (Norland Stratec 
Medizintechnik, GmbH, Birkenfeld, Germany). Mid-shaft 
and distal regions of femur and tibia were scanned. All 
scans were performed using the developed protocol 
designed for studying isolated small bones(8). Total bone 
mineral densities (BMD), trabecular BMD, total 
cross-sectional area, trabecular cross-sectional area and 
stress-strain index (SSI) in the distal/proximal were 
determined. 
 
IV. Rat Osteoblastic UMR-106 Cell Culture Study 
 
UMR-106 cells (ATCC no. CRL-1661) were cultured 
in Dulbecco’s Modified Eagle Medium (DMEM) 
supplemented with 10% fetal bovine serum (FBS), 
penicillin 100 U/mL and streptomycin 100 µg/mL at 37oC 
in a humidified atmosphere of 95% air and 5% CO2 as 
previously described(7). After 48 h, the medium was 
changed to phenol-red free DMEM supplemented with 1% 
dextran-charcoal-stripped serum (sFBS) for 24 h. The cells 
were then treated with RDTF extract (0.02 to 0.2 µg/mL), 
17β-estradiol (10 nM) or vehicle in the presence or 
absence of ICI 182, 780 (1 µM) for 48 h before treatment. 
Cell proliferation of UMR 106 cells were studied by using 
MTS (3-(4,5-dimethylthiazol -2-yl)-5-(3-carboxymethoxyphenyl)
-2-(4-sulfophenyl)-2H tetrazolium) assay (Promega, 
#G3580). ALP activity was measured directly on the 
monolayer of cell cultures. 100 µL per well of PBS 
containing 10 mM p-nitrophenylphosphate (PNP) was 
added and shaken for 30 minutes at 37oC. The absorbance 
of colour change was measured at 405nm in a microplate 
reader. To normalize the result, Bradford protein assay was 
carried out and ALP activity was expressed in a unit of 
U/L/µg protein.  
 
V. Transient Transfection and Estrogen Receptors (ER) 
Mediated Luciferase Activity Assay 
 
The cells were transfected by LipofectamineTM 2000 
reagent as previously described(9). ER-α, ER-β and 
ERE-containing luciferase reporter plasmid vERETkluc 
were kindly provided by Dr. Vincent Giguere (McGill 
University, Montreal, Quebec, Canada). After 6 hours of 
transfection, the cells were treated with vehicle, 
17β-estradiol (10 nM) or RDTF extract (0.2 µg/mL) for  
24 h. Cells were then lysed with passive lysis buffer and 
luciferase activity was measured using Dual Luciferase 
Reporter Assay System (Promega Corporation, Madison, 
MI, USA) and the signal was detected by TD-20/20 
Luminometer (Turner Design, Sunnyvale, CA, USA). The 
estrogen promoter activity was expressed as Firefly 





Treated cells were harvested and lysed with passive 
lysis buffer (Promega, Madison, MI, USA) as previously 
described(9). Protein concentrations were determined using 
Bradford assay. Equal amounts of proteins were separated 
by SDS-PAGE on a 10 % reducing gel at a constant 
voltage (200 V) for about an hour, and transblotted onto 
polyvinylidene fluoride fluoropolymer (PVDF) 
membranes (Immobilin-P, Millipore Corp., Ma, USA). The 
blots were probed with monoclonal rabbit anti-human 
phosphor-ER-α at serine 118 residues (1 : 2000) or 
anti-human ER-α (1 : 3000), and followed by incubation 
with goat anti-rabbit conjugated with horseradish 
peroxidase (1 : 2000). The antigen-antibody complexes 
were then detected with enhanced chemiluminescence 
(ECL) reagent and visualized by the Lumi-Imager using 
Lumi-Analyst version 3.10 software (Roche, Mannheim, 
Germany). 
 
VII. Statistical Analysis 
 
The in vivo data were analyzed one-way ANOVA 
followed by Tukey’s post test and the in vitro data were 
analyzed by the non-paired student’s t-test between control 
group and each treatment group using Graphpad PRISM® 
software package. Results were expressed as Mean ± SEM 
(standard error mean). p-values < 0.05 were considered as 
significant.  
RESULTS AND DISCUSSION 
 
The present study evaluated the osteoprotective 
effects and mechanism of actions of the total flavonoid 
fraction of Rhizoma Drynariae in ovariectomized mice and 
in rat osteoblast-like UMR 106 cells. Our results clearly 
demonstrated that RDTF could suppress OVX-induced 
loss in bone mass in OVX mice. In particular, treatment of 
OVX mice with RDTF at 0.087, 0.173 or 0.346 mg/g/day 
significantly increased total BMD and trabecular BMD at 
both distal femur and proximal tibia. The increase was 
most significant with RDTF at 0.173 mg/g/day (medium 
dose) at distal femur as shown in Table 1.  
 
Table 1. Effects of RD Total flavonoid extract on Total Bone Mineral 
Density of distal femur and proximal tibia in Sham and OVX mice. 
 Total BMD (mg/cm) 
 Distal Femur Proximal Tibia 
OVX (Veh) 335.2 + 6.5 a 240.9 + 5.9 a 
E2 453.4 + 8.5 c 325.5 + 12.7 c 
RD TF (Low) 377.4 + 4.5 b 267.9 + 5.4 b 
RD TF (Med) 395.6 + 4.8 b 300.0 + 4.1 b 
RD TF (High) 394.3 + 7.2 b 270.9 + 11.9 b 
Sham (Veh) 394.3 + 7.2 b 283.7 + 9.8 b 
Results were analyzed by one-way ANOVA and expressed as mean + 
SEM (n = 8) a p < 0.05 vs OVX (Veh), b p < 0.05 vs Sham Veh), c p < 
0.05 vs OVX (Veh) and Sham (Veh). 
 
According to the normal daily uptake of flavonoids in 
human (9 mg/kg/day), our dosages used was about 10, 20 
and 40-fold higher than normal. Some studies in China 
talked about the acute and chronic effect of administrating 
RDTF in mice. Zhao et al.(10) found the LD50 was 66-fold 
higher from normal daily human uptake of total flavonoids 
in mice. Our dosages were regarded as safe to eat. Zhao et 
al.(11) also reported another publication about the chronic 
toxicology test. The experimental mice, which they were 
fed by RDTF in 60, 80 and 540-fold higher than normal, 
did not have obvious side-effect. After all, RDTF is 
regarded as safe to consume in terms of both short and 
prolong time frame.  
Our study showed that RDTF mimicked estrogen in 
stimulating cell proliferation and ALP activity via estrogen 
receptor (ER) in UMR 106 cells. As shown in Figure 2A 
and Figure 2B, RDTF at both 0.02 and 0.2 mg/mL 
increased osteoblastic cell proliferation as well as alkaline 
phosphatase activities (osteoblastic differentiation) in 
UMR 106 cells, and the increase were abolished in the 
presence of ICI 182, 780, a specific estrogen receptor 
antagonist. These results suggest that the stimulatory 
effects of RDTF on osteoblastic fucntions in UMR 106 
cells were estrogen receptor dependent. The results were in 

























Figure 2. The effect of Rhizoma Drynaria total flavonoids on 
UMR106 a) cell proliferation and b) cell differentiation in the pres 
ence and absence of estrogen antagonists. ^^^ p < 0.001 vs C, ** and 
*** p < 0.01 and p < 0.001 vs corresponding dosage without blocker 
treatment. 
 
Jeong et al.(12) demonstrated that crude extract of RD was 
shown to promote osteoblast differentiation and 
mineralization in pre-osteoblastic MC3T3-E1 cells through 
regulation of bone morphogenetic protein-2. Similarly, 
Zhang et al.(13) showed that serum from RDTF treated rats 
significantly promoted proliferation and differentiation of 
cultured osteoblasts extracted from newborn Sprague 
Dawley rats in a time dependent manner. 
To determine if RDTF could activate estrogen 
receptor and activate estrogen response element (ERE)- 
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(standard error mean). p-values < 0.05 were considered as 
significant.  
RESULTS AND DISCUSSION 
 
The present study evaluated the osteoprotective 
effects and mechanism of actions of the total flavonoid 
fraction of Rhizoma Drynariae in ovariectomized mice and 
in rat osteoblast-like UMR 106 cells. Our results clearly 
demonstrated that RDTF could suppress OVX-induced 
loss in bone mass in OVX mice. In particular, treatment of 
OVX mice with RDTF at 0.087, 0.173 or 0.346 mg/g/day 
significantly increased total BMD and trabecular BMD at 
both distal femur and proximal tibia. The increase was 
most significant with RDTF at 0.173 mg/g/day (medium 
dose) at distal femur as shown in Table 1.  
 
Table 1. Effects of RD Total flavonoid extract on Total Bone Mineral 
Density of distal femur and proximal tibia in Sham and OVX mice. 
 Total BMD (mg/cm) 
 Distal Femur Proximal Tibia 
OVX (Veh) 335.2 + 6.5 a 240.9 + 5.9 a 
E2 453.4 + 8.5 c 325.5 + 12.7 c 
RD TF (Low) 377.4 + 4.5 b 267.9 + 5.4 b 
RD TF (Med) 395.6 + 4.8 b 300.0 + 4.1 b 
RD TF (High) 394.3 + 7.2 b 270.9 + 11.9 b 
Sham (Veh) 394.3 + 7.2 b 283.7 + 9.8 b 
Results were analyzed by one-way ANOVA and expressed as mean + 
SEM (n = 8) a p < 0.05 vs OVX (Veh), b p < 0.05 vs Sham Veh), c p < 
0.05 vs OVX (Veh) and Sham (Veh). 
 
According to the normal daily uptake of flavonoids in 
human (9 mg/kg/day), our dosages used was about 10, 20 
and 40-fold higher than normal. Some studies in China 
talked about the acute and chronic effect of administrating 
RDTF in mice. Zhao et al.(10) found the LD50 was 66-fold 
higher from normal daily human uptake of total flavonoids 
in mice. Our dosages were regarded as safe to eat. Zhao et 
al.(11) also reported another publication about the chronic 
toxicology test. The experimental mice, which they were 
fed by RDTF in 60, 80 and 540-fold higher than normal, 
did not have obvious side-effect. After all, RDTF is 
regarded as safe to consume in terms of both short and 
prolong time frame.  
Our study showed that RDTF mimicked estrogen in 
stimulating cell proliferation and ALP activity via estrogen 
receptor (ER) in UMR 106 cells. As shown in Figure 2A 
and Figure 2B, RDTF at both 0.02 and 0.2 mg/mL 
increased osteoblastic cell proliferation as well as alkaline 
phosphatase activities (osteoblastic differentiation) in 
UMR 106 cells, and the increase were abolished in the 
presence of ICI 182, 780, a specific estrogen receptor 
antagonist. These results suggest that the stimulatory 
effects of RDTF on osteoblastic fucntions in UMR 106 
cells were estrogen receptor dependent. The results were in 

























Figure 2. The effect of Rhizoma Drynaria total flavonoids on 
UMR106 a) cell proliferation and b) cell differentiation in the pres 
ence and absence of estrogen antagonists. ^^^ p < 0.001 vs C, ** and 
*** p < 0.01 and p < 0.001 vs corresponding dosage without blocker 
treatment. 
 
Jeong et al.(12) demonstrated that crude extract of RD was 
shown to promote osteoblast differentiation and 
mineralization in pre-osteoblastic MC3T3-E1 cells through 
regulation of bone morphogenetic protein-2. Similarly, 
Zhang et al.(13) showed that serum from RDTF treated rats 
significantly promoted proliferation and differentiation of 
cultured osteoblasts extracted from newborn Sprague 
Dawley rats in a time dependent manner. 
To determine if RDTF could activate estrogen 
receptor and activate estrogen response element (ERE)- 
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dependent transcription, UMR 106 cells were transfected 
with ERE-luciferase construct and co-transfected with 
plasmids that encode for either ER or ER. As shown in 
Figure 3, RDTF at 0.2 g/mL but not 0.02 g/mL 
significantly induced ERE-dependent luciferase activities 














Figure 3. The effect of Rhizoma Drynaria total flavonoids on ER-α 
and ER-β-mediated ERE-dependent luciferase activity in UMR106 
cells. * p < 0.05 vs C (ER-α) ^^ p < 0.01 vs C (ER-β). 
 
Recent studies showed that ER could be activated in 
the absence of ligand binding by modulating various signal 
transduction pathways such as the mitogen-activated 
protein kinase (MAPK) mediated pathways(14-16). Upon 
activation of unliganded ERα by MAPK cascade, ERα was 
shown to be phosphorylated at serine residue 118 (Ser118), 
104 (Ser104) and 167 (Ser167) within the AF-1 domain of 
ERα(17). To determine if RDTF activates ER 
ligand-independently, the ratio of phosphorylated ERα 
(Ser118) to total ERα expression in UMR 106 cells in 
response to RDTF treatment was studied. As shown in 
Figure 4, 0.2 g/mL RDTF as well as 10-8M E2 
significantly induced ER phosphorylation at serine 118 ER 
and decreased the expression of ER in UMR 106 cells.  
ER phosphorylation at Ser118 was preferentially chosen as 
Ser118 is a highly conserved residue that represents the 
major site of phosphorylation in response to estradiol(18). 
Our results clearly indicated that RDTF at 0.2 g/mL 
could activate ER phosphorylation in UMR 106 cells, 
suggesting that RDTF could also activate ER 
ligand-independently in osteoblastic cells.  
The present study clearly demonstrated RDTF is 
effective in protecting against ovarietomy-induced bone 
loss in mice and exerts direct effects in regulating 
osteoblastic cell growth via the activation of ER. Our study 
clearly identified the optimal dose of RDTF for achieving 
bone protective effects in ovariectomized mice to be 0.173 
mg/g/day and demonstrated that RDTF could activate ER 
in both ligand dependent as well as ligand-independent 
manner. Future studies will be needed to evaluate the 
clinical efficacy of RDTF for treatment of osteoporosis in 
postmenopausal women.  
 
ACKNOWLEDGMENTS 
We thank the State Key Laboratory of Chinese 
Medicine and Molecular Pharmacology, Shenzhen for its 
support. This work was supported by the National Science 
Foundation China/ Research Grant Council (N_PolyU536 
/04), HKSAR and the Niche Area Fund from The Hong 
Kong Polytechnic University (I-BB8N). 
REFERENCES 
1. Lau, E. M. and Cooper, C. 1996. The epidemiology 
of osteoporosis. The oriental perspective in a world 
context. Clin. Orthop. Relat. Res. 323: 65-74. 
2. Gass, M. and Dawson-Hughes, B. 2006. Preventing 
osteoporosis-related fractures: an overview. Am. J. 
Med. 119: S3-S11. 
3. Glasier, A. 2006. HRT and breast cancer. Womens 
Health Med. 13: 15-17. 
4. Jeong, J. C., Lee, J. W., Yoon, C. H., Kim, H. M. 
and Kim, C. H. 2004. Drynariae Rhizoma promotes 
osteoblast differentiation and mineralization in 
MC3T3-E1 cells through regulation of bone 
morphogenetic protein-2, alkaline phosphatase, type 
I collagen and collagenase-1. Toxicol. In Vitro 18: 
829-834 
5. Wong, R. W. and Rabie, A. B. 2006. Systemic effect 
of crude extract from rhizome of Drynaria fortune on 
bone formation in mice. Phytother. Res. 20: 
313-315. 
6. Sun, J.. He, W. and Liu, K. 2008. The research of 
Drynaria total flavonoids and osteoporosis research. 
Chinese J. Osteoporosis 14: 763-766. 
7. Xie, F., Wu, C. F., Lai, W. P., Yang, X. J., Cheung, 
P. Y., Yao, X. S., Leung, P. C. and Wong, M. S. 
2005. The osteoprotective effect of Herba epimedii 
(HEP) extract in vivo and in vitro. Evid. Based 
Complement. Alternat. Med. 2: 353-361. 
8. Gasser, J. 2002. Bone measurements by peripheral 
quantitative computed tomography in rodents. 
Methods Mol. Med. 80: 323-341. 
Dual luciferase assay













Figure 4. The effect of Rhizoma Drynaria total flavonoids on 
the expression of phosphorylation of ER-α in UMR106 cells. 
9. Lau, W. S., Chan, R. Y., Guo, D. A. and Wong, M. S. 
2008. Ginsenoside Rg1 exerts estrogen-like activities 
via ligand-independent activation of ERalpha 
pathway. J. Steroid Biochem. Mol. Biol. 108: 64-71. 
10. Zhao, J., Xie, Y., Zhang, W., Wang, Z. and Liu, Y. 
2005. Acute Toxicity Test of Total Flavonoids from 
Rhizome of Drynariae. Herald Med. 24: 12-14. 
11. Zhao, H., Xie, Y., Zhang, W. J., Wang, G. Z. and Lir, 
Y. 2004. Chronic Toxicity Test of total flavnoids 
from Rhizoma Drynariae. J. Health Toxicol. 18: 
301-302. 
12. Jeong, J. C., Lee, J. W., Yoon, C. H., Kim, H. M. 
and Kim, C. H. 2004. Drynariae Rhizoma promotes 
osteoblast differentiation and mineralization in 
MC3T3-E1 cells through regulation of bone 
morphogenetic protein-2, alkaline phosphatase, type 
I collagen and collagenase-1. Toxicol. In Vitro  18: 
829-834. 
13. Zhang, J., Li, H. P., Yang, P. L., Liu, Y. H. and 
Yang, B. H. 2009. Effects of total flavonoids from 
Rhizoma Drynariae medicated serum on 
proliferation, differentiation, cell cycle and apoptosis 
of osteoblasts in vitro. Zhong Yao Cai   32: 
1090-1093. 
14. Lau, W. S., Chan, R. Y., Guo, D. A. and Wong, M. S. 
2008. Ginsenoside Rg1 exerts estrogen-like activities 
via ligand-independent activation of ERalpha 
pathway. J. Steroid Biochem. Mol. Biol.  108: 
64-71. 
15. Bunone, G., Briand, P. A., Miksicek, R. J. and 
Picard, D. 1996. Activation of the unliganded 
estrogen receptor by EGF involves the MAP kinase 
pathway and direct phosphorylation. EMBO J. 15: 
2174-2183. 
16. Kato, S., Endoh, H., Masuhiro, Y., Kitamoto, T., 
Uchiyama, S., Sasaki, H., Masushige, S., Gotoh, Y., 
Nishida, E., Kawashima, H., Metzger, D. and 
Chambon, P. 1995. Activation of the estrogen 
receptor through phosphorylation by 
mitogen-activated protein kinase. Science 270: 
1491-1494. 
17. Chen, D. S., Washbrook, E., Sarwar, N., Bates, G. J., 
Pace, P. E., Thirunuvakkarasu, V., Taylor, J., 
Epstein, R. J., Fuller-Pace, F. V., Egly, J. M., 
Coombes, R. C. and Ali, S. 2002. Phosphorylation of 
human estrogen receptor  at serine 118 by two 
distinct signal transduction pathways revealed by 
phosphorylation- specific antisera. Oncogene 21: 
4921-4931. 
18. Lannigan, D. A. 2003. Estrogen receptor 
phosphorylation. Steroids 68: 1-9.
Journal of Food and Drug Analysis, Vol. 20, Suppl. 1, 2012268
??????????????????? ???????????? ??????????
dependent transcription, UMR 106 cells were transfected 
with ERE-luciferase construct and co-transfected with 
plasmids that encode for either ER or ER. As shown in 
Figure 3, RDTF at 0.2 g/mL but not 0.02 g/mL 
significantly induced ERE-dependent luciferase activities 














Figure 3. The effect of Rhizoma Drynaria total flavonoids on ER-α 
and ER-β-mediated ERE-dependent luciferase activity in UMR106 
cells. * p < 0.05 vs C (ER-α) ^^ p < 0.01 vs C (ER-β). 
 
Recent studies showed that ER could be activated in 
the absence of ligand binding by modulating various signal 
transduction pathways such as the mitogen-activated 
protein kinase (MAPK) mediated pathways(14-16). Upon 
activation of unliganded ERα by MAPK cascade, ERα was 
shown to be phosphorylated at serine residue 118 (Ser118), 
104 (Ser104) and 167 (Ser167) within the AF-1 domain of 
ERα(17). To determine if RDTF activates ER 
ligand-independently, the ratio of phosphorylated ERα 
(Ser118) to total ERα expression in UMR 106 cells in 
response to RDTF treatment was studied. As shown in 
Figure 4, 0.2 g/mL RDTF as well as 10-8M E2 
significantly induced ER phosphorylation at serine 118 ER 
and decreased the expression of ER in UMR 106 cells.  
ER phosphorylation at Ser118 was preferentially chosen as 
Ser118 is a highly conserved residue that represents the 
major site of phosphorylation in response to estradiol(18). 
Our results clearly indicated that RDTF at 0.2 g/mL 
could activate ER phosphorylation in UMR 106 cells, 
suggesting that RDTF could also activate ER 
ligand-independently in osteoblastic cells.  
The present study clearly demonstrated RDTF is 
effective in protecting against ovarietomy-induced bone 
loss in mice and exerts direct effects in regulating 
osteoblastic cell growth via the activation of ER. Our study 
clearly identified the optimal dose of RDTF for achieving 
bone protective effects in ovariectomized mice to be 0.173 
mg/g/day and demonstrated that RDTF could activate ER 
in both ligand dependent as well as ligand-independent 
manner. Future studies will be needed to evaluate the 
clinical efficacy of RDTF for treatment of osteoporosis in 
postmenopausal women.  
 
ACKNOWLEDGMENTS 
We thank the State Key Laboratory of Chinese 
Medicine and Molecular Pharmacology, Shenzhen for its 
support. This work was supported by the National Science 
Foundation China/ Research Grant Council (N_PolyU536 
/04), HKSAR and the Niche Area Fund from The Hong 
Kong Polytechnic University (I-BB8N). 
REFERENCES 
1. Lau, E. M. and Cooper, C. 1996. The epidemiology 
of osteoporosis. The oriental perspective in a world 
context. Clin. Orthop. Relat. Res. 323: 65-74. 
2. Gass, M. and Dawson-Hughes, B. 2006. Preventing 
osteoporosis-related fractures: an overview. Am. J. 
Med. 119: S3-S11. 
3. Glasier, A. 2006. HRT and breast cancer. Womens 
Health Med. 13: 15-17. 
4. Jeong, J. C., Lee, J. W., Yoon, C. H., Kim, H. M. 
and Kim, C. H. 2004. Drynariae Rhizoma promotes 
osteoblast differentiation and mineralization in 
MC3T3-E1 cells through regulation of bone 
morphogenetic protein-2, alkaline phosphatase, type 
I collagen and collagenase-1. Toxicol. In Vitro 18: 
829-834 
5. Wong, R. W. and Rabie, A. B. 2006. Systemic effect 
of crude extract from rhizome of Drynaria fortune on 
bone formation in mice. Phytother. Res. 20: 
313-315. 
6. Sun, J.. He, W. and Liu, K. 2008. The research of 
Drynaria total flavonoids and osteoporosis research. 
Chinese J. Osteoporosis 14: 763-766. 
7. Xie, F., Wu, C. F., Lai, W. P., Yang, X. J., Cheung, 
P. Y., Yao, X. S., Leung, P. C. and Wong, M. S. 
2005. The osteoprotective effect of Herba epimedii 
(HEP) extract in vivo and in vitro. Evid. Based 
Complement. Alternat. Med. 2: 353-361. 
8. Gasser, J. 2002. Bone measurements by peripheral 
quantitative computed tomography in rodents. 
Methods Mol. Med. 80: 323-341. 
Dual luciferase assay













Figure 4. The effect of Rhizoma Drynaria total flavonoids on 
the expression of phosphorylation of ER-α in UMR106 cells. 
9. Lau, W. S., Chan, R. Y., Guo, D. A. and Wong, M. S. 
2008. Ginsenoside Rg1 exerts estrogen-like activities 
via ligand-independent activation of ERalpha 
pathway. J. Steroid Biochem. Mol. Biol. 108: 64-71. 
10. Zhao, J., Xie, Y., Zhang, W., Wang, Z. and Liu, Y. 
2005. Acute Toxicity Test of Total Flavonoids from 
Rhizome of Drynariae. Herald Med. 24: 12-14. 
11. Zhao, H., Xie, Y., Zhang, W. J., Wang, G. Z. and Lir, 
Y. 2004. Chronic Toxicity Test of total flavnoids 
from Rhizoma Drynariae. J. Health Toxicol. 18: 
301-302. 
12. Jeong, J. C., Lee, J. W., Yoon, C. H., Kim, H. M. 
and Kim, C. H. 2004. Drynariae Rhizoma promotes 
osteoblast differentiation and mineralization in 
MC3T3-E1 cells through regulation of bone 
morphogenetic protein-2, alkaline phosphatase, type 
I collagen and collagenase-1. Toxicol. In Vitro  18: 
829-834. 
13. Zhang, J., Li, H. P., Yang, P. L., Liu, Y. H. and 
Yang, B. H. 2009. Effects of total flavonoids from 
Rhizoma Drynariae medicated serum on 
proliferation, differentiation, cell cycle and apoptosis 
of osteoblasts in vitro. Zhong Yao Cai   32: 
1090-1093. 
14. Lau, W. S., Chan, R. Y., Guo, D. A. and Wong, M. S. 
2008. Ginsenoside Rg1 exerts estrogen-like activities 
via ligand-independent activation of ERalpha 
pathway. J. Steroid Biochem. Mol. Biol.  108: 
64-71. 
15. Bunone, G., Briand, P. A., Miksicek, R. J. and 
Picard, D. 1996. Activation of the unliganded 
estrogen receptor by EGF involves the MAP kinase 
pathway and direct phosphorylation. EMBO J. 15: 
2174-2183. 
16. Kato, S., Endoh, H., Masuhiro, Y., Kitamoto, T., 
Uchiyama, S., Sasaki, H., Masushige, S., Gotoh, Y., 
Nishida, E., Kawashima, H., Metzger, D. and 
Chambon, P. 1995. Activation of the estrogen 
receptor through phosphorylation by 
mitogen-activated protein kinase. Science 270: 
1491-1494. 
17. Chen, D. S., Washbrook, E., Sarwar, N., Bates, G. J., 
Pace, P. E., Thirunuvakkarasu, V., Taylor, J., 
Epstein, R. J., Fuller-Pace, F. V., Egly, J. M., 
Coombes, R. C. and Ali, S. 2002. Phosphorylation of 
human estrogen receptor  at serine 118 by two 
distinct signal transduction pathways revealed by 
phosphorylation- specific antisera. Oncogene 21: 
4921-4931. 
18. Lannigan, D. A. 2003. Estrogen receptor 
phosphorylation. Steroids 68: 1-9.
9. Lau, W. S., Chan, R. Y., Guo, D. A. and Wong, M. S. 
2008. Ginsenoside Rg1 exerts estrogen-like activities 
via ligand-independent activation of ERalpha 
pathway. J. Steroid Biochem. Mol. Biol. 108: 64-71. 
10. Zhao, J., Xie, Y., Zhang, W., Wang, Z. and Liu, Y. 
2005. Acute Toxicity Test of Total Flavonoids from 
Rhizome of Drynariae. Herald Med. 24: 12-14. 
11. Zhao, H., Xie, Y., Zhang, W. J., Wang, G. Z. and Lir, 
Y. 2004. Chronic Toxicity Test of total flavnoids 
from Rhizoma Drynariae. J. Health Toxicol. 18: 
301-302. 
12. Jeong, J. C., Lee, J. W., Yoon, C. H., Kim, H. M. 
and Kim, C. H. 2004. Drynariae Rhizoma promotes 
osteoblast differentiation and mineralization in 
MC3T3-E1 cells through regulation of bone 
morphogenetic protein-2, alkaline phosphatase, type 
I collagen and collagenase-1. Toxicol. In Vitro  18: 
829-834. 
13. Zhang, J., Li, H. P., Yang, P. L., Liu, Y. H. and 
Yang, B. H. 2009. Effects of total flavonoids from 
Rhizoma Drynariae medicated serum on 
proliferation, differentiation, cell cycle and apoptosis 
of osteoblasts in vitro. Zhong Yao Cai   32: 
1090-1093. 
14. Lau, W. S., Chan, R. Y., Guo, D. A. and Wong, M. S. 
2008. Ginsenoside Rg1 exerts estrogen-like activities 
via ligand-independent activation of ERalpha 
pathway. J. Steroid Biochem. Mol. Biol.  108: 
64-71. 
15. Bunone, G., Briand, P. A., Miksicek, R. J. and 
Picard, D. 1996. Activation of the unliganded 
estrogen receptor by EGF involves the MAP kinase 
pathway and direct phosphorylation. EMBO J. 15: 
2174-2183. 
16. Kato, S., Endoh, H., Masuhiro, Y., Kitamoto, T., 
Uchiyama, S., Sasaki, H., Masushige, S., Gotoh, Y., 
Nishida, E., Kawashima, H., Metzger, D. and 
Chambon, P. 1995. Activation of the estrogen 
receptor through phosphorylation by 
mitogen-activated protein kinase. Science 270: 
1491-1494. 
17. Chen, D. S., Washbrook, E., Sarwar, N., Bates, G. J., 
Pace, P. E., Thirunuvakkarasu, V., Taylor, J., 
Epstein, R. J., Fuller-Pace, F. V., Egly, J. M., 
Coombes, R. C. and Ali, S. 2002. Phosphorylation of 
human estrogen receptor  at serine 118 by two 
distinct signal transduction pathways revealed by 
phosphorylation- specific antisera. Oncogene 21: 
4921-4931. 
18. Lannigan, D. A. 2003. Estrogen receptor 
phosphorylation. Steroids 68: 1-9.
Journal of Food and Drug Analysis, Vol. 20, Suppl. 1, 2012 269
??????????????????? ???????????? ??????????
